In CRC, a combination of BRAF p.V600E inhibitor encorafenib, EGFR inhibitor cetuximab, and MEK inhibitor binimetinib resulted in significantly longer mOS and higher overall response rate (ORR) compared to standard therapy [38]. Here, BRAF is linked to colorectal carcinoma.